Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history.
Sánchez-Luceros
Analía
A
Departamento de Hemostasia y Trombosis, Instituto de Investigaciones, Hematológicas Mariano R. Castex, Academia Nacional de Medicina, Buenos Aires, Argentina. sanchezluceros@hematologia.anm.edu.ar
Meschengieser
Susana S
SS
Turdó
Karina
K
Arizó
Adriana
A
Woods
Adriana I
AI
Casais
Patricia
P
Blanco
Alicia N
AN
Kempfer
Ana C
AC
Lazzari
María A
MA
D000293:Adolescent; D000328:Adult; D001778:Blood Coagulation Disorders / Q000175:diagnosis* / Q000517:prevention & control; D015331:Cohort Studies; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005169:Factor VIII / Q000378:metabolism; D005260:Female; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D011256:Pregnancy Outcome; D011263:Pregnancy Trimester, Third; D012189:Retrospective Studies; D014841:von Willebrand Factor / Q000235:genetics* / Q000378:metabolism*
D006490:Hemostatics; D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin